To assess the contribution of these death receptor/ligand interactions, we utilized blocking antibodies against Fas (to prevent FasL on CTLs from binding Fas on AML cells) or TRAIL (to prevent TRAIL on CTLs from binding its receptors on AML cells). The gene discussed is FAS; the disease is acute myeloid leukemia.